Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5676637 | 0.78 | ADORA1 (0.64) | ADORA1ALDH1A1MAPTLMNAHSD17B10 | |
| SCHEMBL1638729 | 0.77 | ALDH1A1 (1.00) | ADORA1ALDH1A1MAPTLMNAHSD17B10 | |
| SCHEMBL5676744 | 0.75 | ADORA1 (0.60) | ADORA1ALDH1A1MAPTLMNAHSD17B10 | |
| SCHEMBL135598 | 0.73 | ALDH1A1 (0.75) | ADORA1ALDH1A1MAPTLMNAHSD17B10 | |
| SCHEMBL4741438 | 0.73 | ALDH1A1 (0.73) | ADORA1ALDH1A1MAPTLMNAHSD17B10 | |
| SCHEMBL5675411 | 0.73 | ALDH1A1 (0.64) | ADORA1ALDH1A1MAPTLMNAHSD17B10 | |
| SCHEMBL11913211 | 0.73 | ADORA1 (0.57) | ADORA1ALDH1A1MAPTLMNAHSD17B10 | |
| SCHEMBL13886683 | 0.72 | ALDH1A1 (0.71) | ADORA1ALDH1A1MAPTLMNAHSD17B10 | |
| SCHEMBL8289781 | 0.72 | MAPT (1.00) | ADORA1ALDH1A1MAPTLMNAHSD17B10 | |
| SCHEMBL881267 | 0.71 | ALDH1A1 (0.71) | ADORA1ALDH1A1MAPTLMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401441-A4 | ALLOSTERIC ADENOSINE RECEPTOR MODULATORS | KING PHARMACEUTICALS RES & DEV (US) | 2006-09-06 | — | — | EP | claimed |
| US-20040077630-A1 | Allosteric adenosine receptor modulators | BARALDI PIER GIOVANNI (IT) | 2004-04-22 | — | — | US | claimed |
| EP-1401441-A2 | ALLOSTERIC ADENOSINE RECEPTOR MODULATORS | King Pharmaceuticals Research and Development Inc. (US) | 2004-03-31 | — | — | EP | claimed |
| US-20020147231-A1 | Allosteric adenosine receptor modulators | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. | 2002-10-10 | — | — | US | claimed |
| WO-2002074056-A2 | ALLOSTERIC ADENOSINE RECEPTOR MODULATORS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC. (US) | 2002-09-26 | — | — | WO | claimed |
| US-20010047008-A1 | Allosteric adenosine receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2001-11-29 | — | — | US | claimed |
| US-7112607-B2 | Allosteric adenosine receptor modulators | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1401441-A4 | ALLOSTERIC ADENOSINE RECEPTOR MODULATORS | KING PHARMACEUTICALS RES & DEV (US) | 2006-09-06 | — | — | EP | disclosed |
| US-6727258-B2 | E.G., KETONE DERIVATIVES OF THIENOTHIOPYRANS, BENZOTHIOPHENES, THIENOPYRIDINES, CYCLOPENTATHIOPHENES, THIOPHENYLNAPHTHALENES, THIOPHENYLBENZOFURANS, ETC. | KING PHARMACEUTICAL RESEARCH & DEVELOPMENT, INC. | 2004-04-27 | — | — | US | disclosed |
| US-20040077630-A1 | Allosteric adenosine receptor modulators | BARALDI PIER GIOVANNI (IT) | 2004-04-22 | — | — | US | disclosed |
| EP-1401441-A2 | ALLOSTERIC ADENOSINE RECEPTOR MODULATORS | King Pharmaceuticals Research and Development Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20020147231-A1 | Allosteric adenosine receptor modulators | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. | 2002-10-10 | — | — | US | disclosed |
| US-20020147185-A1 | Allosteric adenosine receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2002-10-10 | — | — | US | disclosed |
| US-20020143004-A1 | Allosteric adenosine receptor modulators | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. | 2002-10-03 | — | — | US | disclosed |
| WO-2002074056-A2 | ALLOSTERIC ADENOSINE RECEPTOR MODULATORS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC. (US) | 2002-09-26 | — | — | WO | disclosed |
| US-20010047008-A1 | Allosteric adenosine receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2001-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147231-A1 | Allosteric adenosine receptor modulators | ADORA2A, ADORA1, ADORA2B | ADORA1 2/4885ALDH1A1 424/4885MAPT 4840/4885 |
| US-20040077630-A1 | Allosteric adenosine receptor modulators | ADORA2A, ADORA1, ADORA2B | ADORA1 2/4885ALDH1A1 291/4885MAPT 4793/4885 |
| US-20010047008-A1 | Allosteric adenosine receptor modulators | ADORA2A, ADORA1, ADORA2B | ADORA1 2/4885ALDH1A1 291/4885MAPT 4793/4885 |
| US-20020143004-A1 | Allosteric adenosine receptor modulators | ADORA2A, ADORA1, ADORA2B | ADORA1 2/4885ALDH1A1 328/4885MAPT 4839/4885 |
| US-20020147185-A1 | Allosteric adenosine receptor modulators | ADORA2A, ADORA1, ADORA2B | ADORA1 2/4885ALDH1A1 328/4885MAPT 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.